Rigel Pharmaceuticals Inc. (RIGL) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, RIGL scores 75 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are: Fundamental Cash Engine at 13/20 (ROIC 28.2%; FCF yield 7.87%); Whale 13F Flow at 16/20 (institutional accumulation and options positioning); Insider Conviction at 17/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 15/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 14/20 (Altman Z 3.64; Piotroski F 7/9; Debt/Equity 0.5).

For a prospective investor, the pillar profile suggests the strongest support comes from insider and institutional flow signals, with the cash engine and balance sheet scoring respectably but with less headroom. The return-on-capital and free-cash-flow yield figures point to a business generating meaningful returns on invested capital, which is an upside driver if sustained. The valuation tradeoff is visible in the EV/EBITDA of 7.3 alongside a market capitalization of $961.1M, while earnings-based multiples are not available in source data, limiting a complete valuation read. The Beta of 1.0 indicates market-level sensitivity per the source, so macro fit is neutral rather than a differentiator. The rating is a quantitative synthesis of the source data and is educational in nature, not personalized financial advice.

Per the SEC financials, revenue and operating income rose across the three reported periods, moving from a loss in FY 2023 to positive operating income in FY 2025. Per the market data, the operating margin is 42.6%, the gross margin is 93.3%, and the net margin is 68%. The ROIC is 28.2%. The Altman Z-Score is 3.64 and the Piotroski F-Score is 7/9 per the Roarable RQD rating, with Debt/Equity at 0.5. Net income in FY 2025 exceeds operating income, a relationship the source does not explain.

Per the recent news and catalysts feed, six items reference RIGL, all from March-era aggregators and dated within the preceding 15 hours of the data timestamp. Headlines include a StockInvest.us price forecast, a Simply Wall St stock analysis, a Yahoo Finance report titled "Rigel Pharmaceuticals Shares Rose Even As Profit Fell," a Seeking Alpha piece on turning "Big Pharma's Castoffs Into A Growth Engine," a TradingView estimates page, and a MarketBeat short-interest update. The Seeking Alpha item is tagged as a CATALYST with a GREEN light; the remaining items are tagged as MARKET WIRE with YELLOW lights. The feed does not describe specific product events, trial readouts, or regulatory dates. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

• What products or pipeline assets generate the reported revenue, and what is the revenue concentration?
• Why does FY 2025 net income ($367.0M) exceed operating income ($125.5M), and what non-operating items drive the difference?
• What is the debt balance, since the financials list debt as N/A despite a Debt/Equity ratio of 0.5?
• What are the EPS and P/E figures, which are unavailable despite the market data showing market capitalization?
• What specific catalysts, trial readouts, or regulatory events are scheduled, given the news feed's general nature?